AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Pacheco Rhonda Janice sold $289K of TAK

Pacheco Rhonda Janice (President, U.S. Business Unit) sold 16,901 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.29M total) on 2026-08-10.

Original reporting
SEC EDGAR · Pacheco Rhonda Janice
Published Aug 13, 2026, 1:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this disclosure does not change company fundamentals or near-term guidance.

02

Market read

A dated insider sale was disclosed via Form 4, offering limited incremental information beyond routine insider-trading monitoring.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings remain substantial (182,507 shares), limiting interpretability.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda’s Form 4 shows officer Rhonda Janice Pacheco sold 16,901 shares at $17.10 on 2026-08-10 for about $289K.

Expected impact

Likely minimal near-term impact; any effect would be limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size is modest versus a large-cap and provides no new operational or guidance information.

Market effects

Sector

No clear sector read-through from a single, modest insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for diversification or taxes; absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the company whose insider transaction was reported.

  • insider
    Rhonda Janice Pacheco

    President, U.S. Business Unit, who reported an open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min